Literature DB >> 22271821

Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Richard B Rothman1, John S Partilla, Michael H Baumann, Catrissa Lightfoot-Siordia, Bruce E Blough.   

Abstract

Several compounds have been identified that display low-efficacy, "partial substrate" activity. Here, we tested the hypothesis that the mechanism of this effect is a slower rate of induced neurotransmitter efflux than that produced by full substrates. Biogenic amine transporter release assays were carried out in rat brain synaptosomes and followed published procedures. [(3)H]1-methyl-4-phenylpyridinium (MPP(+)) was used to assess release from dopamine (DA) and norepinephrine nerve terminals, whereas [(3)H]5-hydroxytryptamine (5-HT) was used to assess release from 5-HT nerve terminals. A detailed time-course evaluation of DA transporter (DAT)-mediated efflux was conducted by measuring the efflux of [(3)H]MPP(+) after the addition of various test compounds. In vivo microdialysis experiments compared the effects of the full substrates [(±)-1-(2-naphthyl)propan-2-amine (PAL-287) and (S)-N-methyl-1-(2-naphthyl)propan-2-amine (PAL-1046)], to that of a partial DAT/5-HT transporter substrate [(S)-N-ethyl-1-(2-naphthyl)propan-2-amine (PAL-1045)] on extracellular DA and 5-HT in the nucleus accumbens of the rat. The in vitro release assays demonstrated that partial substrate activity occurs at all three transporters. In the DAT efflux experiments, D-amphetamine (full substrate) promoted a fast efflux (K1 = 0.24 min(-1)) and a slow efflux (K2 = 0.008 min(-1)). For the partial DAT substrates, K1 = ∼0.04 min(-1), and K2 approximated zero. The in vivo microdialysis experiments showed that the partial substrate (PAL-1045) was much less effective in elevating extracellular DA and 5-HT than the comparator full substrates. We conclude that low-efficacy partial DAT substrates promote efflux at a slower rate than full substrates, and "partiality" reflects the ultra-slow K2 constant, which functionally limits the ability of these compounds to increase extracellular DA. We speculate that partial biogenic amine transporter substrates bind to the transporter but are less effective in inducing conformational changes required for reverse transport activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271821      PMCID: PMC3364510          DOI: 10.1124/jpet.111.188946

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

2.  The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter.

Authors:  M E Reith; J L Berfield; L C Wang; J V Ferrer; J A Javitch
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

3.  Evidence for noncompetitive modulation of substrate-induced serotonin release.

Authors:  Richard B Rothman; Michael H Baumann; Bruce E Blough; Arthur E Jacobson; Kenner C Rice; John S Partilla
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

4.  Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

Authors:  R B Rothman; M H Baumann; C M Dersch; D V Romero; K C Rice; F I Carroll; J S Partilla
Journal:  Synapse       Date:  2001-01       Impact factor: 2.562

5.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

6.  Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.

Authors:  J Shawn Goodwin; Gaynor A Larson; Jarod Swant; Namita Sen; Jonathan A Javitch; Nancy R Zahniser; Louis J De Felice; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

Review 7.  The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango.

Authors:  Harald H Sitte; Michael Freissmuth
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

8.  Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter.

Authors:  Kyle C Schmitt; Sreeman Mamidyala; Swati Biswas; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2010-01-12       Impact factor: 5.372

9.  Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release.

Authors:  Richard B Rothman; Christina M Dersch; Subramaniam Ananthan; John S Partilla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

10.  Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner.

Authors:  Christian Pifl; Alexandra Wolf; Patrick Rebernik; Harald Reither; Michael L Berger
Journal:  Neuropharmacology       Date:  2008-10-26       Impact factor: 5.250

View more
  17 in total

1.  Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.

Authors:  Bruce E Blough; Antonio Landavazo; John S Partilla; Michael H Baumann; Ann M Decker; Kevin M Page; Richard B Rothman
Journal:  ACS Med Chem Lett       Date:  2014-04-15       Impact factor: 4.345

2.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

3.  Characterization of in vitro phase I metabolites of methamnetamine in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.

Authors:  Young-Ki Hong; Young-Hoon Kim; Jin-Moo Lee; Hye Hyun Yoo; Sun-Ok Choi; Mi Sun Kang
Journal:  Int J Legal Med       Date:  2021-04-29       Impact factor: 2.686

Review 4.  Using Ca2+-channel biosensors to profile amphetamines and cathinones at monoamine transporters: electro-engineering cells to detect potential new psychoactive substances.

Authors:  Tyler W E Steele; Jose M Eltit
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

Review 5.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 6.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

7.  Assessment of the abuse potential of methamnetamine in rodents: a behavioral pharmacology study.

Authors:  Dong-Hyun Youn; Jin Mook Kim; Young-Ki Hong; Seo-In Park; Jin-Moo Lee; Young-Hoon Kim; Chang Won Park; Mi Sun Kang
Journal:  Psychopharmacology (Berl)       Date:  2021-04-03       Impact factor: 4.530

Review 8.  Overview of Monoamine Transporters.

Authors:  Shaili Aggarwal; Ole V Mortensen
Journal:  Curr Protoc Pharmacol       Date:  2017-12-20

Review 9.  Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.

Authors:  Kyle C Schmitt; Richard B Rothman; Maarten E A Reith
Journal:  J Pharmacol Exp Ther       Date:  2013-04-08       Impact factor: 4.030

10.  Alpha-ethyltryptamines as dual dopamine-serotonin releasers.

Authors:  Bruce E Blough; Antonio Landavazo; John S Partilla; Ann M Decker; Kevin M Page; Michael H Baumann; Richard B Rothman
Journal:  Bioorg Med Chem Lett       Date:  2014-07-29       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.